Dorling Janet 4
4 · CymaBay Therapeutics, Inc. · Filed Dec 11, 2023
Insider Transaction Report
Form 4
Dorling Janet
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-12-11$20.07/sh−6,000$120,422→ 0 total - Exercise/Conversion
Common Stock
2023-12-11$4.63/sh+6,000$27,780→ 6,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-12-11−6,000→ 67,000 totalExercise: $4.63Exp: 2031-04-04→ Common Stock (6,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on August 9, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.823 to $20.81, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The option grant vests as to 1/36 of the underlying shares monthly from April 5, 2021.